At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed May 15, 2026 at 08:00 ET
CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at 6 months and 85.7% CR in CIS patients, with no grade 3+ TRAEs. The data support a potential intravesical combination regimen but remain early and require durability follow-up.
- HG-EFS of 96.0% at 3 months and 89.5% at 6 months in ITT population (median follow-up 6.6 months)
- CR rate of 85.7% in CIS-containing ITT population (95% CI 67.3%-96.0%) and 92.3% in efficacy-evaluable population (95% CI 74.9%-99.1%)
- No grade 3 or greater treatment-related adverse events reported; favorable safety profile
- Data to be presented at AUA 2026; durability data expected later in 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access